Abstract
This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Current Alzheimer Research
Title: Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Volume: 3 Issue: 3
Author(s): Illana Gozes and Irit Spivak-Pohis
Affiliation:
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Abstract: This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Export Options
About this article
Cite this article as:
Gozes Illana and Spivak-Pohis Irit, Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632790
DOI https://dx.doi.org/10.2174/156720506777632790 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Medicinal Inorganic Chemistry: Identification of New Targets in Drug Discovery)
Current Topics in Medicinal Chemistry Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Current Alzheimer Research Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science Aging Affects Nicotinic Acetylcholine Receptors in Brain
Central Nervous System Agents in Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Conformational Diseases: Structural Studies of Aggregation of Polyglutamine Proteins
Current Computer-Aided Drug Design Editorial [Hot topic: Transgenic Animal Models of Neurodegenerative Diseases (Guest Editor: Stephen D. Skaper)]
CNS & Neurological Disorders - Drug Targets Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Autoimmune Neuromuscular Disorders
Current Neuropharmacology Evaluation of the Binding Affinity of a Gonadotropin-Releasing Hormone Analogue (GnRH-a) Buserelin through <i>In silico</i> and <i>In vivo</i> Testing in <i>Clarias magur</i>
Current Proteomics Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Biological Activity of Some Volatile Diterpenoids
Current Bioactive Compounds Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy